ImmunoMet Therapeutics Announces the Appointment of Jason Jungsik Song M.D., Ph.D. to the Scientific Advisory Board > Investors & Media

본문 바로가기


Investors & Media

ImmunoMet Therapeutics Announces the Appointment of Jason Jungsik Song M.D., Ph.D. to the Scientific Advisory Board

Date :
October 5, 2016

 

news_logo.png

 

 

ImmunoMet Therapeutics Announces the Appointment of Jason

Jungsik Song M.D., Ph.D. to the Scientific Advisory Board

 

Houston, TX, October 5, 2016 -- ImmunoMet Therapeutics, a development stage

biotechnology company focused on immuno-oncology and immune cell metabolism,

today announced the appointment of Jason Jungsik Song M.D., Ph.D. to its

Scientific Advisory Board (SAB). Dr. Song is a preeminent immunologist and

professor at Yonsei University, Seoul, Korea. He trained in internal medicine at

Yonsei University where he earned his M.D. and Ph.D., and he completed a

rheumatology fellowship at Stanford University, CA, USA. 

 

 

Dr. Song specializes in various autoimmune diseases, patients’ immune profiling

and the investigation of metabolic pathways to control the immune system. Dr.

Song achieved a major discovery by uncovering the importance of

immunometabolism in autoimmune diseases, and he has participated in the

development of the immuno-oncology drugs at ImmunoMet.

 

Sung-wuk Kim, Chief Executive Officer at ImmunoMet Therapeutics, said, “We are

delighted to have Dr. Jason Jungsik Song, a leading expert in clinical immunology,

as a member of our SAB, and we look forward to his contributions to the Company.

Dr. Song will provide valuable experience to the Company on translational research

bridging clinical immunology with immuno-oncology. His expertise will be helpful

to guide the Company’s novel approach to develop combination therapies in

immuno-oncology that focus on difficult-to-treat relapse and drug resistant cancer,

improving response rates of anti-PD1, PD-L1 therapies and providing new options

with immune cell metabolism medicines. 

 

"I am pleased to join the Scientific Advisory Board at ImmunoMet and to work with

the management team to advance the science behind immune activation that

selectively targets immune suppressor cells," said Dr. Song. "I am enthusiastic

about the potential of clinical immunology, which is complementary in the search

and evaluation for small molecules to be used in combination with anti-PD1

antibodies to treat certain cancers.” 

 

About ImmunoMet Therapeutics


ImmunoMet Therapeutics, a development stage biotechnology company, is

dedicated to developing innovative oncology products to improve the quality of

life and make a meaningful difference in the lives of cancer patients. The

Company, a spinoff of HanAll BioPharma and headquartered in Houston, is focused

on immuno-oncology targeting immune suppressor cells (ISC) and immune cell

metabolism, which are designed to enhance anti-cancer immunity, disrupt cancer

cell growth, and reverse immunosuppression in tumor microenvironments. The

Company’s novel technology addresses the high unmet medical need to treat drug

resistant, relapse cancers and improve response rates of immuno-oncology

treatments. For more information about the Company, please visit

www.immunomet.com

 

Contact


Sanghee Yoo: shyoo@immunomet.com    

Joseph T. Schepers:  919-616-1923, joeschepers@immunomet.com 

 

 


Copyright © ImmunoMet. All rights reserved.